Scrip
Eisai seeks US paediatric exclusivity for Dacogen
07 July 2009
Ian Haydock
Please Login to read the full article.
07 July 2009
Ian Haydock
Eisai is to begin a paediatric clinical trial with its cancer product Dacogen (decitabine), with the aim of securing a six-month extension to the product's US exclusivity period.
The planned study, for paediatric acute myelogenous leukaemia (AML), follows a formal written request from the...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Sustained release Aricept and eribulin key near-term R&D projects for Eisai
- US FDA warns Eisai for overstating efficacy of Dacogen in promotion
- Cervarix, Prevenar and Januvia among new Japanese approvals
- Genzyme's Clolar needs more study in acute myeloid leukaemia, US panel says
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
